Wholly Owned Pipeline

PureTech's Wholly Owned Programs are designed to harness immunological and lymphatic system mechanisms for the treatment of lung dysfunction, oncology, lymphatic, neurological and neuropsychological disorders.

Wholly Owned Pipeline

Our programs
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
LYT-100
Deupirfenidone
IPF & other progressive fibrosing ILDs

2

IPF & other progressive fibrosing ILDs

140–250K U.S. (PF-ILD including IPF) 


Product candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis and disorders of lymphatic flow, including lung dysfunction conditions (e.g., idiopathic pulmonary fibrosis (IPF), unclassifiable interstitial lung diseases (uILDs), Long COVID respiratory complications and related sequelae) and lymphedema.

LYT-100
Deupirfenidone
Long COVID1 respiratory complications & related sequelae

2

Long COVID respiratory complications & related sequelae

Product candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis and disorders of lymphatic flow, including lung dysfunction conditions (e.g., idiopathic pulmonary fibrosis (IPF), unclassifiable interstitial lung diseases (uILDs), Long COVID respiratory complications and related sequelae) and lymphedema.
LYT-100
Deupirfenidone
Lymphatic flow disorders, including lymphedema

2

Lymphatic flow disorders, incl. lymphedema

~1M U.S.

Product candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis and disorders of lymphatic flow, including lung dysfunction conditions (e.g., idiopathic pulmonary fibrosis (IPF), unclassifiable interstitial lung diseases (uILDs), Long COVID respiratory complications and related sequelae) and lymphedema.
LYT-200
Anti-Galectin-9 MAb
Solid tumors

1

Solid tumors

>50K/year U.S. (Metastatic CRC)
>28K/year U.S. (Metastatic pancreatic cancer)
>4K/year U.S. (Metastatic cholangiocarcinoma)


LYT-200 is a monoclonal antibody targeting a foundational immunosuppressive protein, galectin-9, for the potential treatment of solid tumors, including pancreatic ductal adenocarcinoma, colorectal cancer and cholangiocarcinoma, that are difficult to treat and have poor survival rates.

LYT-210
Anti-Delta-1 MAb
Solid tumors

Preclinical

Solid tumors

>50K/year U.S. (Metastatic CRC)
>28K/year U.S. (Metastatic pancreatic cancer)
>4K/year U.S. (Metastatic cholangiocarcinoma)


LYT-210 is a fully human IgG1 mAb directed against the δ1 chain of T cells bearing γδT cell receptors (TCRs) we are designing for antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis (ADCP).

LYT-300
Oral Allopregnanolone
Neurological indications

Preclinical

Neurological indications

LYT-300 is an oral form of FDA-approved allopregnanolone, a natural neurosteroid, that may be applicable to a range of neurological conditions.
Phase completedPhase in progressRegistration-enabling studies planned

 

1. Long COVID is a term being used to describe the emerging and persistent complications following the resolution of COVID-19 infection. 

The BIG Idea - Moving medicine forward at PureTech

Collaborative drug discovery based on proprietary biological insights
Rapid & cost-efficient prioritization & validation
Develop internally, partner or spin-out
Collaborative drug discovery based on proprietary biological insights
Rapid & cost-efficient prioritization & validation
Develop internally, partner or spin-out

Relationships with several pharma companies or their investment arms